In accordance with Article 16 (1) of the “Korean Depository Receipt Agreement” signed between Access Bio and Korea Securities Depository on March 11, 2013, the Record Date for determining shareholders in 2020 is December 31, 2020.
Category: NEWS
Post
CARESTART™ IGM/IGG ANTIBODY TEST GRANTED EUA AUTHORIZATION
Global Leader in Infectious Disease Diagnosis Receives FDA EUA for Serology Test Capable of Determining Subjects’ past COVID-19 Exposure and Immunoresponse within 10 Minutes
Post
GETTING TESTS WHERE THEY’RE NEEDED MOST
Access Bio was founded on the basic principle of cherishing life and health for all people. The company has emerged as a leader in the diagnosis of infectious diseases. Although it provides a comprehensive portfolio, Access Bio is known for its work against malaria, HIV, HPV, and now, COVID-19.